Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00635817 · ClinicalTrials.gov registry record · Phase 3
A Study of Leuprolide 11.25 mg and 30 mg Administered Every 3 Months to Treat Central Precocious Puberty
A Phase 3 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 3
- Development phase
- 84
- Enrollment target
NCT00635817 is a Phase 3 study that has completed, run by Abbott. The registered enrollment target is 84 participants.
The verdict
NCT00635817, a Phase 3 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 84 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if 11.25 and 30 mg formulations of leuprolide are effective in treating children with Central Precocious Puberty (CPP).
Interventions
- DRUG Leuprolide acetate 11.25 mg
- DRUG Leuprolide acetate 30 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2008-06 |
| Est. Completion | 2010-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00635817
The ClinicalTrials.gov registry entry for NCT00635817 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Leuprolide acetate 11.25 mg is the first listed.
NCT00635817 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00635817 about?
NCT00635817 is a clinical study titled "A Study of Leuprolide 11.25 mg and 30 mg Administered Every 3 Months to Treat Central Precocious Puberty". The purpose of this study is to determine if 11.25 and 30 mg formulations of leuprolide are effective in treating children with Central Precocious Puberty (CPP).
What is the current status of trial NCT00635817?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 84 participants. The study started on 2008-06. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00635817?
The interventions under investigation include: Leuprolide acetate 11.25 mg (DRUG), Leuprolide acetate 30 mg (DRUG).
Who is sponsoring clinical trial NCT00635817?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.